ORIC Pharmaceuticals Inc ORIC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
-
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Trading Information
- Previous Close Price
- $10.94
- Day Range
- $10.38–11.17
- 52-Week Range
- $7.23–14.93
- Bid/Ask
- $10.30 / $11.15
- Shares Outstanding
- 103.52M
- Market Cap
- $1.12B
- Volume/Avg
- 2,228 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 104
- Website
- https://www.oricpharma.com
Valuation
|
Metric
|
ORIC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.71 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ORIC
|
|---|---|
Quick Ratio | 15.86 |
Current Ratio | 16.33 |
Interest Coverage | — |
Quick Ratio
ORIC
Profitability
|
Metric
|
ORIC
|
|---|---|
Return on Assets (Normalized) | −29.42% |
Return on Equity (Normalized) | −31.37% |
Return on Invested Capital (Normalized) | −31.08% |
Return on Assets
ORIC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n%t<TcL | LOCK|B#g@? | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$^>@&#l | LOCK|KF@Q | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<VsMWt | LOCK|%Sf | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|R%pPXmq | LOCK|$>sm | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!K!$@h! | LOCK|BK | $36B | |||
| Moderna Inc
MRNA
| LOCK|R!k%^j | LOCK|K> | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@K?@%#$ | LOCK|>%fN | $25B | |||
| Incyte Corp
INCY
| LOCK|T#YYcd | LOCK|Ld | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|TgNnPz | LOCK|$! | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|c>??N&z | LOCK|^Z< | $17B |
United States